Abstract
Celyad recently initiated several clinical trials with the CYAD-01 product, a natural killer group 2D (NKG2D)-based chimeric antigen receptor (CAR), in both solid and hematologic tumor types. This review discusses the unique properties of CYAD-01, expecting to provide a new paradigm to fight against solid tumors.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.
MeSH terms
-
Clinical Trials as Topic / methods
-
Drug Approval
-
Drug Industry
-
Humans
-
Immunotherapy, Adoptive* / methods
-
Immunotherapy, Adoptive* / trends
-
Neoplasms / immunology
-
Neoplasms / therapy*
-
Receptors, Chimeric Antigen / genetics
-
Receptors, Chimeric Antigen / metabolism
-
Receptors, Chimeric Antigen / therapeutic use*
-
Research Design
-
T-Lymphocytes / physiology*
-
T-Lymphocytes / transplantation
-
Therapies, Investigational* / methods
-
Therapies, Investigational* / trends
-
United States
-
United States Food and Drug Administration
Substances
-
Receptors, Chimeric Antigen